MYNERVA

Reduce Pain and falls through AI-driven neurostimulation

The loss of peripheral sensations, affecting diabetic peripheral neuropathy (DPN)(237 M patients), is a severe risk factor for altered gait biomechanics, balance impairment, increased falls risk and chronic pain development.
MYNERVA produced a peerless revolutionary non-invasive device to tackle all these symptoms, Leia: a groundbreaking device that offers a reprieve from the vicious cycle of pain and sensory loss. It is a wearable neurostimulating device able to restore the sense of touch and alleviate pain through pleasant, non-invasive AI-driven electrical stimulation, all within the familiar form factor of a sock.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
Milestone

01.11.2023

prototype

Deal

20.10.2022

IP

Deal

21.05.2022

clinical validation

No Jobs

No videos and documents

No Awards

MYNERVA

Reduce Pain and falls through AI-driven neurostimulation

Headquarter:
zurich

Foundation Date:
June 2025

Technology:

  • Medtech

Sectors:

  • Digital Health
  • Hardware
  • Machine Learning / AI
  • Medtech

Support received

  • Support venture leaders